Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Paul Chapman, Martin Madaus

Premium

Quanterix has named Paul Chapman as its new president and CEO. In the latter role, Chapman replaces Martin Madaus who will remain as executive chairman of the privately held firm's board of directors.

In his new roles, Chapman will oversee the commercialization of Quanterix's Simoa technology (see related story, this issue). He joins Quanterix from EMD Millipore, where he was vice president of its BioPharm Process Solutions business. Prior to joining Millipore, he was vice president of hospital solutions for Roche Near Patient Testing in Austria. Chapman was also the international business development manager at Roche Molecular Diagnostics for blood screening and held a number of sales and marketing positions at Roche Diagnostics Canada, where he began his career in 1993.

Chapman holds a BSc in microbiology from the University of Western Ontario, a BSc in immunology from the University of Guelph in Ontario, and graduated from the marketing management program at the Richard Ivy School of Business in London, Ontario.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.